Mycobacteria and Biological Response Modifiers: Two Sides of the Relationship

Infectious Disease Clinics of North America

Volumn 25, Issue 4, 2011, Pages 865-893

  Sundareshan, Vidya ^a   Modi, Jignesh ^a   Khardori, Nancy Misri ^b  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Adjunct therapy; Biological response modifiers; Mycobacteria; Reactivation

Indexed keywords

BACTERIAL VACCINE; BIOLOGICAL RESPONSE MODIFIER; COMPLEMENT RECEPTOR; DNA VACCINE; ENZYME INHIBITOR; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A SYNTHASE; IMMUNOGLOBULIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; ISONIAZID; LYMPHOTOXIN; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN; PLACEBO; RETINOL; STEROID; THALIDOMIDE; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VITAMIN D;

ADAPTIVE IMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DRUG MEGADOSE; DRUG TARGETING; GRANULOMA; HUMAN; IMMUNOTHERAPY; INFECTION RISK; INNATE IMMUNITY; LYMPHOCYTE FUNCTION; MACROPHAGE; MYCOBACTERIOSIS; MYCOBACTERIUM VACCAE; NEUTROPHIL; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN FUNCTION; REVIEW; TH1 CELL; TH2 CELL; TUBERCULOSIS;

CYTOKINES; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION; MACROPHAGES; MYCOBACTERIUM INFECTIONS;

EID: 80455177251     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2011.07.010     Document Type: Review

References (164)

1. Lönnroth K., Raviglione M. Global epidemiology of tuberculosis: prospects for control. Semin Respir Crit Care Med 2008, 29(5):481-491.
2. Horsburgh C.R., O'Donnell M., Chamblee S., et al. Revisiting rates of reactivation tuberculosis: a population-based approach. Am J Respir Crit Care Med 2010, 182(3):420-425.
3. Comstock G.W. Epidemiology of tuberculosis. Am Rev Respir Dis 1982, 125:8.
4. Dye C., Floyd K., Uplekar M. Global tuberculosis control 2008, WHO/HTM/TB/2008.393, World Health Organization, Geneva (Switzerland).
5. Guelar A., Gatell J.M., Verdejo J., et al. A prospective study of the risk of tuberculosis among HIV-infected patients. AIDS 1993, 7:1345.
6. Antonucci G., Girardi E., Raviglione M.C., et al. Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. The Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA). JAMA 1995, 274:143.
7. Jick S.S., Lieberman E.S., Rahman M.U., et al. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 2006, 55(1):19.
8. Lichtenstein I.H., MacGregor R.R. Mycobacterial infections in renal transplant recipients: report of five cases and review of the literature. Rev Infect Dis 1983, 5(2):216.
9. Malaviya A.N., Nigil H. Infections associated with the use of biologic response modifiers in rheumatic diseases: a critical appraisal. Indian Journal of Rheumatology 2011, 6(1 Suppl):99-112.
10. Tomioka H., Namba K. Kekkaku 2006, 81(12):753-774. [review], [in Japanese].
11. Mootoo A., Stylianou E., Arias M.A., et al. TNF-alpha in tuberculosis: a cytokine with a split personality. Inflamm Allergy Drug Targets 2009, 8(1):53-62.
12. Flynn J.L., Chan J. Immunology of tuberculosis. Annu Rev Immunol 2001, 19:93-129.
13. Wolf A.J., Linas B., Trevejo-Nuñez G.J., et al. Mycobacterium tuberculosis infects dendritic cells with high frequency and impairs their function in vivo. J Immunol 2007, 179:2509-2519.
14. Hart P.D., Armstrong J.A., Brown C.A., et al. Ultrastructural study of the behaviour of macrophages toward parasitic mycobacteria. Infect Immun 1972, 5:803-807.
15. Cohn Z.A. The fate of bacteria within phagocytic cells. I. The degradation of isotopically labeled bacteria by polymorphonuclear leucocytes and macrophages. J Exp Med 1963, 117:27-42.
16. Chan J., Xing Y., Magliozzo R.S., et al. Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J Exp Med 1992, 175(4):1111.
17. Armstrong J.A., Hart P.D. Response of cultured macrophages to Mycobacterium tuberculosis, with observations on fusion of lysosomes with phagosomes. J Exp Med 1971, 134:713.
18. Raja A. Immunology of tuberculosis. Indian J Med Res 2004, 120:213-232.
19. Pancholi P., Mirza A., Schauf V., et al. Presentation of mycobacterial antigens by human dendritic cells: lack of transfer from infected macrophages. Infect Immun 1993, 61(12):5326.
20. Armstrong J.A., Hart P.D. Phagosome-lysosome interactions in cultured macrophages infected with virulent tubercle bacilli. Reversal of the usual nonfusion pattern and observations on bacterial survival. J Exp Med 1975, 142(1):1.
21. Schlesinger L.S. Role of mononuclear phagocytes in M. tuberculosis pathogenesis. J Investig Med 1996, 44:312-323.
22. Schlesinger L.S., Hull S.R., Kaufman T.M. Binding of the terminal mannosyl units of lipoarabinomannan from a virulent strain of Mycobacterium tuberculosis to human macrophages. J Immunol 1994, 152:4070-4079.
23. Wojtas B., Fijalkowska B., Wlodarczyk A., et al. Mannosylated lipoarabinomannan balances apoptosis and inflammatory state in mycobacteria-infected and uninfected bystander macrophages. Microb Pathog 2011, 51(1-2):9-21.
24. Barnes P.F., Modlin R.L., Ellner J.J. T-cell responses and cytokines. Tuberculosis: pathogenesis, protection and control 1994, 417-435. ASM Press, Washington, DC, 225. B.R. Bloom (Ed.).
25. Hoheisel G., Zheng L., Teschler H., et al. Increased soluble CD14 levels in BAL fluid in pulmonary tuberculosis. Chest 1995, 108:1614-1616.
26. Walker L., Lowrie D.B. Killing of Mycobacterium microti by immunologically activated macrophages. Nature 1981, 293:69-70.
27. Selvaraj P., Swamy R., Vijayan V.K., et al. Hydrogen peroxide producing potential of alveolar macrophages and blood monocytes in pulmonary tuberculosis. Indian J Med Res 1988, 88:124-129.
28. MacMicking J.D., North R.J., LaCourse R., et al. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc Natl Acad Sci U S A 1997, 94:5243-5248.
29. Vishwanath V., Meera R., Puvanakrishnan R., et al. Fate of Mycobacterium tuberculosis inside rat peritoneal macrophages in vitro. Mol Cell Biochem 1997, 175:169-175.
30. Chan J., Fan X.D., Hunter S.W., et al. Lipoarabinomannan, a possible virulence factor involved in persistence of Mycobacterium tuberculosis within macrophages. Infect Immun 1991, 59(5):1755.
31. Schlesinger L.S. Macrophage phagocytosis of virulent but not attenuated strains of Mycobacterium tuberculosis is mediated by mannose receptors in addition to complement receptors. J Immunol 1993, 150(7):2920.
32. Yuan Y., Lee R.E., Besra G.S., et al. Identification of a gene involved in the biosynthesis of cyclopropanated mycolic acids in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 1995, 92(14):6630.
33. Manca C., Tsenova L., Barry C.E., et al. Mycobacterium tuberculosis CDC1551 induces a more vigorous host response in vivo and in vitro, but is not more virulent than other clinical isolates. J Immunol 1999, 162(11):6740.
34. Sturgill-Koszycki S., Schlesinger P.H., Chakraborty P., et al. Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase. Science 1994, 263(5147):678.
35. Xu S., Cooper A., Sturgill-Koszycki S., et al. Intracellular trafficking in Mycobacterium tuberculosis and Mycobacterium avium-infected macrophages. J Immunol 1994, 153(6):2568.
36. Noll H., Bloch H., Asselinea U.J., et al. The chemical structure of the cord factor of Mycobacterium tuberculosis. Biochim Biophys Acta 1956, 20(2):299.
37. Douvas G.S., Looker D.L., Vatter A.E., et al. Gamma interferon activates human macrophages to become tumoricidal and leishmanicidal but enhances replication of macrophage-associated mycobacteria. Infect Immun 1985, 50(1):1.
38. Rook G.A., Steele J., Fraher L., et al. Vitamin D3, gamma interferon, and control of proliferation of Mycobacterium tuberculosis by human monocytes. Immunology 1986, 57(1):159.
39. Rao S., Koirala J., Khardori N., et al. Biological response modifiers as adjunct treatment for refractory localized mycobacterium avium complex infection. J Investig Med 2005, 53(Suppl 2):S398.
40. Gardam M.A., Keystone E.C., Menzies R., et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003, 3(3):148.
41. Long R., Gardam M. Tumour necrosis factor-alpha inhibitors and the reactivation of latent tuberculosis infection. CMAJ 2003, 168(9):1153.
42. Keane J., Gershon S., Wise R.P., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001, 345(15):1098.
43. Mohan V.P., Scanga C.A., Yu K., et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun 2001, 69:1847-1855.
44. Flynn J.L., Goldstein M.M., Chan J., et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995, 2(6):561-572.
45. Bean A.G., Roach D.R., Briscoe H., et al. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol 1999, 162:3504.
46. Ogata K., Linzer B.A., Zuberi R.I., et al. Activity of defensins from human neutrophilic granulocytes against Mycobacterium avium-Mycobacterium intracellulare. Infect Immun 1992, 60:4720-4725.
47. Bermudez L.E., Young L.S. Natural killer cell-dependent mycobacteriostatic and mycobactericidal activity in human macrophages. J Immunol 1991, 146:265-270.
48. Nirmala R., Narayanan P.R., Mathew R., et al. Reduced NK activity in pulmonary tuberculosis patients with/without HIV infection: Identifying the defective stage and studying the effect of interleukins on NK activity. Tuberculosis 2001, 81:343-352.
49. Medzhitov R., Preston-Hurlburt P., Janeway C.A. A human homologue of the Drosophila toll protein signals activation of adaptive immunity. Nature 1997, 388(6640):394.
50. Edwards D., Kirkpatrick C.H. The immunology of mycobacterial diseases. Am Rev Respir Dis 1986, 134:1062-1071.
51. Means T.K., Wang S., Lien E., et al. Human toll-like receptors mediate cellular activation by Mycobacterium tuberculosis. J Immunol 1999, 163(7):3920.
52. Underhill D.M., Ozinsky A., Smith K.D., et al. Toll-like receptor-2 mediates mycobacteria-induced proinflammatory signaling in macrophages. Proc Natl Acad Sci U S A 1999, 96(25):14459.
53. Liu P.T., Stenger S., Li H., et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006, 311:1770.
54. Takeda K., Kaisho T., Akira S. Toll-like receptors. Annu Rev Immunol 2003, 21:335.
55. Uma Devi K.R., Ramalingam B., Raja A. Qualitative and quantitative analysis of antibody response in childhood tuberculosis against antigens of Mycobacterium tuberculosis. Indian J Med Microbiol 2002, 20:145-149.
56. Randhawa P.S. Lymphocyte subsets in granulomas of human tuberculosis: an in situ immunofluorescence study using monoclonal antibodies. Pathology 1990, 22:153-155.
57. Yu C.T., Wang C.H., Huang T.J., et al. Relation of bronchoalveolar lavage T lymphocyte subpopulations to rate of regression of active pulmonary tuberculosis. Thorax 1995, 50:869-874.
58. Taha R.A., Kotsimbos T.C., Song Y.L., et al. IFN-gamma and IL-12 are increased in active compared with inactive tuberculosis. Am J Respir Crit Care Med 1997, 155:1135-1139.
59. Stenger S., Mazzaccaro R.J., Uyemura K., et al. Differential effects of cytolytic T cell subsets on intracellular infection. Science 1997, 276:1684-1687.
60. Uma Devi K.R., Ramalingam B., Raja A. Antibody response to Mycobacterium tuberculosis 30 and 16kDa antigens in pulmonary tuberculosis with human immunodeficiency virus coinfection. Diagn Microbiol Infect Dis 2003, 46:205-209.
61. Hirsch C.S., Toossi Z., Johnson J.L., et al. Augmentation of apoptosis and interferon G production at sites of active Mycobacterium tuberculosis infection in human tuberculosis. J Infect Dis 2001, 183:779-788.
62. Hirsch C.S., Toossi Z., Vanham G., et al. Apoptosis and T cell hyporesponsiveness in pulmonary tuberculosis. J Infect Dis 1999, 179:945-953. 64.
63. Sulochana D., Deepa S., Prabha C. Cell proliferation and apoptosis: dual-signal hypothesis tested in tuberculous pleuritis using mycobacterial antigens. FEMS Immunol Med Microbiol 2004, 41:85-92.
64. Varadhachary A.S., Perdow S.N., Hu C., et al. Differential ability of T cell subsets to undergo activation-induced cell death. Proc Natl Acad Sci U S A 1997, 94:5778-5783.
65. McKinney J.D., Jacobs W.R., Bloom B.R. Persisting problems in tuberculosis. Emerging infections 1998, 51-146. Academic Press, San Diego (CA). R.M. Krause (Ed.).
66. Andersen P., Munk M.E., Pollock J.M., et al. Specific immune-based diagnosis of tuberculosis. Lancet 2000, 356(9235):1099.
67. Barnes P.F. Diagnosing latent tuberculosis infection: turning glitter to gold. Am J Respir Crit Care Med 2004, 170(1):5.
68. Doherty T.M., Demissie A., Olobo J., et al. Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients. J Clin Microbiol 2002, 40(2):704.
69. Ladel C.H., Szalay G., Riedel D., et al. Interleukin-12 secretion by Mycobacterium tuberculosis infected macrophages. Infect Immun 1997, 65:1936-1938.
70. Cooper A.M., Magram J., Ferrante J., et al. Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with Mycobacterium tuberculosis. J Exp Med 1997, 186:39-45.
71. Ottenhof T.H., Kumararatne D., Casanova J.L. Novel human immunodeficiencies reveal the essential role of type-1 cytokines in immunity to intracellular bacteria. Immunol Today 1998, 19:491-494.
72. Flesch I., Kaufmann S.H. Mycobacterial growth inhibition by interferon-gamma-activated bone marrow macrophages and differential susceptibility among strains of Mycobacterium tuberculosis. J Immunol 1987, 138:4408-4413.
73. Cooper A.M., Dalton D.K., Stewart T.A., et al. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 1993, 178:2243-2247.
74. Blanchard D.K., Michelini-Norris M.B., Pearson C.A., et al. Production of granulocyte-macrophage colony-stimulating factor (GM-CSF) by monocytes and large granular lymphocytes stimulated with Mycobacterium avium-M. intracellulare: activation of bactericidal activity by GM-CSF. Infect Immun 1991, 59:2396-2402.
75. Jouanguy E., Altare F., Lamhamedi S., et al. Interferon-γ-receptor deficiency in an infant with fatal bacille Calmette-Guérin infection. N Engl J Med 1996, 335:1956-1961.
76. Lin Y., Zhang M., Hofman F.M., et al. Absence of a prominent Th2 cytokine response in human tuberculosis. Infect Immun 1996, 64:1351-1356.
77. Zhang M., Lin Y., Iyer D.V., et al. T cell cytokine responses in human infection with Mycobacterium tuberculosis. Infect Immun 1995, 63:3231-3234.
78. Sodhi A., Gong J., Silva C., et al. Clinical correlates of interferon gamma production in patients with tuberculosis. Clin Infect Dis 1997, 25:617-620.
79. Garcia I., Miyazaki Y., Marchal G., et al. High sensitivity of transgenic mice expressing soluble TNFR1 fusion protein to mycobacterial infections: synergistic action of TNF and IFN-gamma in the differentiation of protective granulomas. Eur J Immunol 1997, 27:3182-3190.
80. Fujiwara H., Kleinhenz M.E., Wallis R.S., et al. Increased interleukin-1 production and monocyte suppressor cell activity associated with human tuberculosis. Am Rev Respir Dis 1986, 133:73-77.
81. Saunders B.M., Frank A.A., Orme I.M., et al. Interleukin-6 induces early gamma interferon production in the infected lung but is not required for generation of specific immunity to Mycobacterium tuberculosis infection. Infect Immun 2000, 68:3322-3326.
82. Rojas M., Olivier M., Gros P., et al. TNFa and IL-10 modulate the induction of apoptosis by virulent Mycobacterium tuberculosis in murine macrophages. J Immunol 1999, 162:6122-6131.
83. Dahl K.E., Shiratsuchi H., Hamilton B.D., et al. Selective induction of transforming growth factor β in human monocytes by lipoarabinomannan of Mycobacterium tuberculosis. Infect Immun 1996, 64:399-405.
84. Ding A., Nathan C.F., Graycar J., et al. Macrophage deactivating factor and transforming growth factor beta 1-beta 2 and beta 3 inhibit induction of macrophage nitrogen oxide synthesis by IFN-gamma. J Immunol 1990, 145:940-944.
85. Rojas R.E., Balaji K.N., Subramanian A., et al. Regulation of human CD4+ αβ T cell receptor positive (TCR+) and γδ TCR+ T-cell responses to Mycobacterium tuberculosis by transforming growth factor β. Infect Immun 1999, 67:6461-6472.
86. Ruscetti F., Varesio L., Ochoa A., et al. Pleiotropic effects of transforming growth factor-beta on cells of the immune system. Ann N Y Acad Sci 1993, 685:488-500.
87. Bonecchi R., Bianchi G., Bordignon P.P., et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 1998, 187:129-134.
88. Lopez Ramirez G.M., Rom W.N., Ciotoli C., et al. Mycobacterium tuberculosis alters expression of adhesion molecules on monocytic cells. Infect Immun 1994, 62:2515-2520.
89. Nau G.J., Guilfoile P., Chupp G.L., et al. A chemoattractant cytokine associated with granulomas in tuberculosis and silicosis. Proc Natl Acad Sci U S A 1997, 94:6414-6419.
90. Spector W.G., Lykke A.W. The cellular evolution of inflammatory granulomata. J Pathol Bacteriol 1966, 92:163-177.
91. Orme I.M., Roberts A.D., Griffin J.P., et al. Cytokine secretion by CD4 T lymphocytes acquired in response to Mycobacterium tuberculosis infection. J Immunol 1993, 151:518-525.
92. Rhoades E.R., Cooper A.M., Orme I.M. Chemokine response in mice infected with Mycobacterium tuberculosis. Infect Immun 1995, 63:3871-3877.
93. Fitzgerald D., Sterlin T., Haas D. Mycobacterium tuberculosis. Principles and practice of infectious diseases 2010, vol. 2:3129. Elsevier, Philadelphia. 7th edition. G.L. Mandell, J.E. Bennett, R. Dolin (Eds.).
94. Sai Baba K.S., Moudgil K.D., Jain R.C., et al. Complement activation in pulmonary tuberculosis. Tubercle 1990, 71:103-107.
95. Iseman M.D. Immunity and pathogenesis Iseman MD. A clinician's guide to tuberculosis 2000, Lippincott Williams & Wilkins, Philadelphia, p. 63-91.
96. Ramanathan V.D., Jawahar M.S., Paramasivan C.N., et al. A histological spectrum of host responses in tuberculous lymphadenitis. Indian J Med Res 1999, 109:212-220.
97. Hopewell P.C., Kato-Maeda M., Mason R.J., et al. Tuberculosis. Murray and Nadel's textbook of respiratory medicine 2010, vol. 1:754-792. Saunders, Philadelphia, (Chapter: 34). 5th edition. R.J. Mason, V.C. Broaddus, T. Martin (Eds.).
98. Mohan A.K., Cote T.R., Siegel J.N., et al. Infectious complications of biologic treatments of rheumatoid arthritis. Curr Opin Rheumatol 2003, 15:179-184.
99. Kwon H.J., Coté T.R., Cuffe M.S., et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003, 138(10):807-811.
100. Tappy L., Chioléro R. Substrate utilization in sepsis and multiple organ failure. Crit Care Med 2007, 35(Suppl 9):S531-S534.
101. Fallahi-Sichani M., Schaller M.A., Kirschner D.E., et al. Identification of key processes that control tumor necrosis factor availability in a tuberculosis granuloma. PLoS Comput Biol 2010, 6(5):e1000778.
102. Wallis R.S., Broder M.S., Wong J.Y., et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004, 38(9):1261.
103. Geyer M., Müller-Ladner U. Rationale of using different biological therapies in rheumatoid arthritis. Arthritis Res Ther 2010, 12(4):214.
104. Kindler V., Sappino A.P., Grau G.E., et al. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989, 56(5):731.
105. Algood H.M., Lin P.L., Flynn J.L. Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis. Clin Infect Dis 2005, 41(Suppl 3):S189.
106. Benini J., Ehlers E.M., Ehlers S. Different types of pulmonary granuloma necrosis in immunocompetent vs. TNFRp55-gene-deficient mice aerogenically infected with highly virulent Mycobacterium avium. J Pathol 1999, 189(1):127.
107. Bopst M., Garcia I., Guler R., et al. Differential effects of TNF and LTalpha in the host defense against M. bovis BCG. Eur J Immunol 2001, 31(6):1935.
108. Gómez-Reino J.J., Carmona L., Valverde V.R., BIOBADASER Group, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003, 48(8):2122.
109. Brassard P., Kezouh A., Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 2006, 43(6):717.
110. Wallis R.S. Reconsidering adjuvant immunotherapy for tuberculosis. Clin Infect Dis 2005, 41(2):201-208.
111. Tubach F., Salmon D., Ravaud P., Research Axed on Tolerance of Biotherapies Group, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009, 60(7):1884.
112. Dixon W.G., Hyrich K.L., Watson K.D., et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010, 69(3):522.
113. Smolen J., Brezezicki J., Mason D., et al. Efficacy and safety of certolizumab pegol in combination with methotrexate (MTX) in patients with active rheumatoid arthritis despite MTX therapy: results from the RAPID 2 study. Ann Rheum Dis 2007, 66(Suppl 2):187.
114. Wallis R.S., Broder M., Wong J., et al. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 2004, 39(8):1254.
115. Centers for Disease Control Prevention (CDC) Trends in tuberculosis-United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2004, 53(10):209.
116. Mohan A.K., Coté T.R., Block J.A., et al. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 2004, 39(3):295-299.
117. Fonseca J.E., Canhão H., Silva C., et al. Acta Reumatol Port 2006, 31(3):247. [in Portuguese].
118. Askling J., Fored C.M., Brandt L., et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005, 52(7):1986.
119. Iseman M.D. Mycobacterial infections in the era of modern biologic agents. Am J Med Sci 2011, 341(4):278-280.
120. Nardell E.A., Wallis R.S. Here today-gone tomorrow: the case for transient acute tuberculosis infection. Am J Respir Crit Care Med 2006, 174(7):734.
121. Coaccioli S., Di Cato L., Marioli D., et al. Impaired cutaneous cell-mediated immunity in newly diagnosed rheumatoid arthritis. Panminerva Med 2000, 42(4):263.
122. Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ?. Semin Arthritis Rheum 2005, 34(5 Suppl 1):12.
123. Ringheanu M., Daum F., Markowitz J., et al. Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn's disease. Inflamm Bowel Dis 2004, 10(6):801.
124. Saliu O.Y., Sofer C., Stein D.S., et al. Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis 2006, 194(4):486.
125. Centers for Disease Control Prevention (CDC) Tuberculosis associated with blocking agents against tumor necrosis factor-alpha-California, 2002-2003. MMWR Morb Mortal Wkly Rep 2004, 53(30):683.
126. Hill P.C., Brookes R.H., Fox A., et al. Large-scale evaluation of enzyme-linked immunospot assay and skin test for diagnosis of Mycobacterium tuberculosis infection against a gradient of exposure in The Gambia. Clin Infect Dis 2004, 38(7):966.
127. Greenberg J.D., Reddy S.M., Schloss S.G., et al. Comparison of an in vitro tuberculosis interferon-gamma assay with delayed-type hypersensitivity testing for detection of latent Mycobacterium tuberculosis: a pilot study in rheumatoid arthritis. J Rheumatol 2008, 35(5):770.
128. Mazurek G.H., Jereb J., Lobue P., Centers for Disease Control Prevention (CDC), et al. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005, 54(RR-15):49.
129. American Thoracic Society (ATS) and the Centers for Disease Control Prevention (CDC) Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999. Am J Respir Crit Care Med 2000, 161:S221.
130. Furst D.E., Keystone E.C., Kirkham B., et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 2008, 67(Suppl 3):iii2-iii25.
131. Garcia Vidal C., Rodríguez Fernández S., Martínez Lacasa J., et al. Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis 2005, 40(5):756.
132. Wallis R.S., van Vuuren C., Potgieter S. Adalimumab treatment of life-threatening tuberculosis. Clin Infect Dis 2009, 48(10):1429-1432.
133. Winthrop K.L., Yamashita S., Beekmann S.E., et al. Infectious Diseases Society of America Emerging Infections Network. Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network. Clin Infect Dis 2008, 46(11):1738.
134. Winthrop K.L., Chang E., Yamashita S., et al. Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy. Emerg Infect Dis 2009, 15(10):1556.
135. Lowrie D.B., Tascon R.E., Bonato V.L., et al. Therapy of tuberculosis vaccine in mice by DNA vaccination. Nature 1999, 400(6741):269-271.
136. Cardona P.J. RUTI: a new chance to shorten the treatment of latent tuberculosis infection. Tuberculosis (Edinb) 2006, 86(3-4):273-289.
137. Nuermberger E., Tyagi S., Williams K.N., et al. Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model. Am J Respir Crit Care Med 2005, 172(11):1452-1456.
138. Hernández-Pando R., Orozco-Esteves H., Maldonado H.A., et al. A combination of a transforming growth factor-beta antagonist and an inhibitor of cyclooxygenase is an effective treatment for murine pulmonary tuberculosis. Clin Exp Immunol 2006, 144(2):264-272.
139. Roy E., Stavropoulos E., Brennan J., et al. Therapeutic efficacy of high-dose intravenous immunoglobulin in Mycobacterium tuberculosis infection in mice. Infect Immun 2005, 73(9):6101-6109.
140. Dlugovitzky D., Stanford C., Stanford J. Immunological basis for the introduction of immunotherapy with Mycobacterium vaccae into the routine treatment of TB. Immunotherapy 2011, 3(4):557-568.
141. Skinner M.A., Yuan S., Prestidge R., et al. Immunization with heat-killed Mycobacterium vaccae stimulates CD8+ cytotoxic T cells specific for macrophages infected with Mycobacterium tuberculosis. Infect Immun 1997, 65(11):4525-4530.
142. Stanford J., Stanford C., Grange J. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis. Front Biosci 2004, 9:1701-1719. [review].
143. Immunotherapy with Mycobacterium vaccae in patients with newly diagnosed pulmonary tuberculosis: a randomised controlled trial. Durban Immunotherapy Trial Group. Lancet 1999, 354(9173):116-119.
144. Johnson J.L., Kamya R.M., Okwera A., et al. Randomized controlled trial of Mycobacterium vaccae immunotherapy in non-human immunodeficiency virus-infected Ugandan adults with newly diagnosed pulmonary tuberculosis. The Uganda-Case Western Reserve University Research Collaboration. J Infect Dis 2000, 181(4):1304-1312.
145. Grahmann P.R., Braun R.K. A new protocol for multiple inhalation of IFN-gamma successfully treats MDR-TB: a case study. The international journal of tuberculosis and lung disease the official journal of the International Union against Tuberculosis and Lung Disease. Int J Tuberc Lung Dis 2008, 12(6):636-644.
146. Assefa A, Bahr G, Rosa Brunet L. Report of the expert consultation on immunotherapeutic interventions for tuberculosis. Meeting report. Geneva, January 29-31, 2007.
147. Giosué S., Casarini M., Alemanno L., et al. Effects of aerosolized interferon-alpha in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 1998, 158(4):1156-1162.
148. Condos R., Rom W.N., Schluger N.W. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol. Lancet 1997, 349(9064):1513-1515.
149. Park S.K., Cho S., Lee I.H., et al. Subcutaneously administered interferon-gamma for the treatment of multidrug-resistant pulmonary tuberculosis. Int J Infect Dis 2007, 11(5):434-440.
150. Johnson J.L., Ssekasanvu E., Okwera A., et al. Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis. Am J Respir Crit Care Med 2003, 168(2):185-191.
151. Katoch K., Singh P., Adhikari T., et al. Potential of Mw as a prophylactic vaccine against pulmonary tuberculosis. Vaccine 2008, 26(9):1228-1234.
152. Patel N., Deshpande M.M., Shah M. Effect of an immunomodulator containing Mycobacterium w on sputum conversion in pulmonary tuberculosis. J Indian Med Assoc 2002, 100(3):191-193.
153. Tsenova L., Bergtold A., Freedman V.H., et al. Tumor necrosis factor alpha is a determinant of pathogenesis and disease progression in mycobacterial infection in the central nervous system. Proc Natl Acad Sci U S A 1999, 96(10):5657-5662.
154. Moreira A.L., Tsenova-Berkova L., Wang J., et al. Effect of cytokine modulation by thalidomide on the granulomatous response in murine tuberculosis. Tuber Lung Dis 1997, 78(1):47-55.
155. Fu L.M., Fu-Liu C.S. Thalidomide and tuberculosis. Int J Tuberc Lung Dis 2002, 6(7):569-572.
156. Schoeman J.F., Andronikou S., Stefan D.C., et al. Tuberculous meningitis-related optic neuritis: recovery of vision with thalidomide in 4 consecutive cases. J Child Neurol 2010, 25(7):822-828.
157. Schoeman J.F., Fieggen G., Seller N., et al. Intractable intracranial tuberculous infection responsive to thalidomide: report of four cases. J Child Neurol 2006, 21(4):301-308.
158. Schoeman J.F., Springer P., van Rensburg A.J., et al. Adjunctive thalidomide therapy for childhood tuberculous meningitis: results of a randomized study. J Child Neurol 2004, 19(4):250-257.
159. Lu H.Z., Li B.Q. Effect of HMG Co A reductase inhibitors on activation of human γδ T cells induced by Mycobacterium tuberculosis antigens. Immunopharmacol Immunotoxicol 2009, 31(3):485-491.
160. Alzeer A.H., FitzGerald J.M. Corticosteroids and tuberculosis: risks and use as adjunct therapy. Tuber Lung Dis 1993, 74(1):6-11.
161. Martineau A.R., Timms P.M., Bothamley G.H., et al. High dose vitamin D3 during intensive-phase antimicrobial treatment for pulmonary tuberculosis: a double-blind randomized controlled trial. Lancet 2011, 377:242-250.
162. Lawson L., Thacher T.D., Yassin M.A., et al. Randomized controlled trial of zinc and vitamin A as co-adjuvants for the treatment of pulmonary tuberculosis. Trop Med Int Health 2010, 15(12):1481-1490.
163. Visset M.E., Grewal H.M., Swart E.C., et al. The effect of vitamin A and zinc supplementation on treatment outcomes in pulmonary tuberculosis: a randomized controlled trial. Am J Clin Nutr 2011, 93(1):93-100.
164. Tarallo M.B., Urquiola C., Monge A., et al. Design of novel iron compounds as potential therapeutic agents against tuberculosis. J Inorg Biochem 2010, 104(11):1164-1170.